Multiple myeloma: Maintenance therapy after autologous hematopoietic stem cell transplantation, depending on minimal residual disease
M. V. Solovyev(Ministry of Health of the Russian Federation), Savchenko Vg(National Research Center for Hematology Russian Academy of Medical Sciences), Э Г Гемджян(National Medical Research Center for Hematology), Irina Galtseva(National Research Center for Preventive Medicine), Larisa A. Kuzmina(Ministry of Health of the Russian Federation), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Н. М. Капранов(National Research Center for Preventive Medicine), Olga S. Pokrovskaya, Maria V. Nareyko(Ministry of Health of the Russian Federation), М. В. Фирсова(Ministry of Health of the Russian Federation), Yulia Davydova(National Research Center for Preventive Medicine)
Cited by 4
Related Papers
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2014|195
Atlas of RNA sequencing profiles for normal human tissues
|Scientific Data|2019|142
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective
|The Oncologist|2010|92
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma
|Leukemia & lymphoma/Leukemia and lymphoma|2015|59